Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

MRKPositive Net Change MRNAPositive Net Change AVEOPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

PFEPositive Net Change MRNAPositive Net Change KMDANegative Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

MRKPositive Net Change MRNAPositive Net Change KMDANegative Net Change BNTXPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

VRTXPositive Net Change MRNAPositive Net Change KMDANegative Net Change CRSPPositive Net Change

Zacks Equity Research

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXPositive Net Change

Zacks Equity Research

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change BNTXPositive Net Change